Table 3 Multivariate analysis of factors associated with serum PlGF and EGF levels.
From: Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer
Training cohort | Validation cohort | |||||||
|---|---|---|---|---|---|---|---|---|
PlGF | EGF | PlGF | EGF | |||||
OR (95%CI) | p | OR (95%CI) | p | OR (95%CI) | p | OR (95%CI) | p | |
Sex | 0.736 (0.397–1.365) | 0.331 | 0.962 (0.480–1.929) | 0.906 | 0.585 (0.297–1.152) | 0.121 | 0.970 (0.503–1.871) | 0.948 |
Age ≤70 [years] | 1.699 (0.898–3.214) | 0.103 | 0.571 (0.287–1.138) | 0.142 | 0.425 (0.215–0.840) | 0.014 | 0.899 (0.463–1.745) | 0.808 |
BMI ≤ 25 [kg/cm2] | 1.041 (0.557–1.946) | 0.901 | 0.903 (0.458–1.782) | 0.769 | 0.439 (0.226–0.852) | 0.015 | 0.953 (0.879–1.032) | 0.234 |
Site of disease | 0.633 (0.329–1.336) | 0.250 | 1.060 (0.541–2.075) | 0.771 | 0.799 (0.369–1.731) | 0.570 | 0.670 (0.318–1.412) | 0.292 |
Neoadjuvant therapy | 0.457 (0.222–0.940) | 0.033 | 0.921 (0.365–2.322) | 0.861 | 0.320 (0.152–0.674) | 0.003 | 0.456 (0.226 − 0.922) | 0.029 |
UICC I/II vs III | 0.876 (0.462–1.626) | 0.656 | 1.668 (0.843–3.330) | 0.142 | 0.937 (0.470–1.870) | 0.880 | 0.844 (0.435–1.636) | 0.597 |
